(Informaci\u00f3n remitida por la empresa firmante)<\/p>\n
\nOnce–daily topical treatment of mild \/ moderate alopecia areata (AA) with 1% STS-01 met the primary efficacy endpoint of >30% Severity of Alopecia Tool (SALT) score improvement compared to patients receiving placebo (p0.0096)<\/p>\n
\nMultiple secondary endpoints met with significant total hair regrowth across the 1% and 2% dose groups<\/p>\n
\nSTS–01 was well tolerated with no major adverse events<\/p>\n
\nSTS–01 has the potential to become the first approved therapy and standard of care for mild \/ moderate alopecia areata, (SALT score 50), which represents over half of the estimated 800,000 AA patients in the US<\/p>\n
\nLONDON, May 30, 2024 \/PRNewswire\/ — Soterios Pharma, a privately held clinical-stage pharmaceutical company, today announced positive topline results from its randomised, placebo-controlled, multi-dose Phase II trial evaluating STS-01 as a treatment for mild \/ moderate AA.<\/p>\n
At 24 weeks, 75.9% of patients treated with once-daily topical dosing of 1% STS-01 met the primary efficacy endpoint (achieving >30% improvement in SALT score) compared to 36.7% receiving placebo (p0.0096). In addition, 19% and 27% of patients on 1% and 2% STS-01, respectively, achieved total hair regrowth (SALT 0), compared to 3% receiving placebo with a clear dose response identified. STS-01 was well tolerated with no major adverse events. Complete study results are expected to be presented at a future medical meeting.<\/p>\n
Arash Mostaghini, Associate Professor of Dermatology at Brigham & Women’s Hospital, said, <\/p>\n
\u00abThese results are extremely encouraging. They validate the potential for STS-01 to provide mild-to- moderate alopecia sufferers with a safe and effective treatment for this debilitating condition. I am also excited by the prospect of targeting total hair regrowth in this patient group.\u00bb<\/p>\n
\nMild \/ moderate alopecia areata (less than 50% hair loss \/ SALT score 50), represents over half of the 800,000 AA patients in the US1 and is associated with a significant disease burden, including depression and anxiety. The impact on quality of life for mild \/ moderate patients is equivalent to those with severe AA2 and yet no approved therapies exist for these patients.<\/p>\n
David Fleet, CEO of Soterios Pharma, said, \u00abThis data gives us clarity and confidence in moving into late-stage clinical development for this product. We thank all the patients, investigators and healthcare staff who participated in this study.\u00bb<\/p>\n
\nAbout Soterios Pharma<\/p>\n
\nSoterios Pharma is a UK-based clinical-stage life sciences company, which is focused on developing and commercialising medicines for dermatology diseases with major unmet needs. https:\/\/www.soteriospharma.com<\/p>\n
\nAbout the Phase II Trial<\/p>\n
\nThe randomised, placebo-controlled, multi-dose Phase II trial evaluated the safety and efficacy of STS-01 in the treatment of mild \/ moderate AA when applied for 24 weeks. A total of 158 participants were randomised to receive one of four doses of STS-01 (0.25%, 0.5%, 1% or 2%) or placebo, with effect being measured based on improvement in the SALT score.<\/p>\n
About STS-01<\/p>\n
\nThe product builds on a mechanism with a well-established safety profile in dermatology, and works through modulating the inflammatory response and the proliferation of T-cells by disruption of the signalling pathways. There is extensive preclinical and clinical evidence to support its efficacy and safety profile in AA.<\/p>\n
Soterios Pharma contacts:<\/p>\n
\nMark Brimble<\/p>\n
\ninfo@soteriospharma.com<\/p>\n
View original content:https:\/\/www.prnewswire.co.uk\/news-releases\/soterios-pharma-announces-positive-topline-results-from-phase-ii-study-of-sts-01-in-the-treatment-of-mild–moderate-alopecia-areata-302157485.html<\/p>\n","protected":false},"excerpt":{"rendered":"
(Informaci\u00f3n remitida por la empresa firmante) Once–daily topical treatment of mild \/ moderate alopecia areata (AA) with 1% STS-01 met the primary efficacy endpoint of >30% Severity of Alopecia Tool (SALT) score improvement compared to patients receiving placebo (p0.0096) Multiple secondary endpoints met with significant total hair regrowth across the 1% and 2% dose groups […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-53058","post","type-post","status-publish","format-standard","hentry","category-noticias"],"_links":{"self":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts\/53058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53058"}],"version-history":[{"count":0,"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts\/53058\/revisions"}],"wp:attachment":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53058"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53058"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}